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The present study was designed to evaluate the oxidative stress as well as the therapeutic eﬀect of Agaricus blazei Muril (A.
Blazei) in rats with streptozotocin-induced diabetes. We used 25 Wistar rats, and DM was induced by injecting streptozotocin
(70mg/Kg i.p.). Agaricus blazei Muril was administered daily starting 40 days after disease onset. A. Blazei w a st e s t e da sa na q u e o u s
extract for its phytochemical composition, and its antioxidant activity in vitro was also evaluated. Lipoperoxidation (LPO), and
superoxide dismutase (SOD), catalase, and glutathione peroxidase activities were measured in the pulmonary tissue, as well as
the presence of inducible nitric oxide synthase (iNOS), through immunohistochemistry. An anatomopathologic study was also
performed.PhytochemicalscreeningofA.Blazeidetectedthepresenceofalkaloidsandsaponins.Theextractexhibitedasigniﬁcant
antioxidant activity in the DPPH-scavenging and the hipoxanthine/xanthine oxidase assays. Pulmonary LPO increased in diabetic
animals (0.43 ± 0.09; P<. 001) as compared to the control group (0.18 ± 0.02), followed by a reduction in the A. Blazei-treated
group (0.33 ± 0.04; P<. 05). iNOS was found increased in the lung in diabetic rats and reduced in the A. Blazei-treated group.
The pulmonary tissue in diabetic rats showed oxidative alterations related to the streptozotocin treatment. The A. Blazei treatment
eﬀectively reduced the oxidative stress and contributed to tissue recovery.
1.Introduction
Diabetes mellitus (DM) is an endocrine metabolic disease of
growingincidenceandclinicalrelevancewithhighmorbidity
and mortality rates [1]. Among its chronic complications are
the micro- and macro vascular disorders related to the renal,
cardiovascular, and nervous systems [2]. However, in the last
two decades, changes in the respiratory function have also
been reported in clinical and experimental studies. Decreases
in the pulmonary function over the years, related to the
decreased measures of pulmonary volumes and capacity,
were evidenced in diabetic patients with impaired metabolic
control [3, 4]. Structural alterations to the basal membrane
of the pulmonary capillary endothelium are also present in
DM, with a thickening of the alveolus-capillary membrane
and reduction in the diﬀusional capability [5, 6]. Moreover,
diabetic patients are more susceptible to lung infections,
in particular tuberculosis, which has a four-times greater
incidence in this particular population [7, 8]. Although all
these alterations were evidenced in clinical and experimental
studies, few studies investigated the main physiopathologic
mechanisms involving pulmonary complications related to
DM.
There are 4 pathways associated with chronic compli-
cations of DM, namely, the polyol pathway, protein kinase
C (PKC) activation, increased ﬂow in the hexosamine2 Experimental Diabetes Research
pathway, and the pathway of advanced glycosilation end-
products (AGE). Although presenting diﬀerently in each
case, oxidative stress (OS) is implicated in the four pathways
cited above [9].
There is plenty of evidence showing that the increase
of nitric oxide (NO), formed by the action of inducible
nitric oxide synthase (iNOS) is one of the factors responsible
for both the pathogenesis and the complications resulting
from DM [10, 11]. The use of exogenous antioxidants may
represent a great therapeutic potential for treatment of DM
[12–14]
The basidiomycete Agaricus blazei Murill (A. Blazei),
popularly known as “sun mushroom”, is native to Brazil and
widely grown in Japan because of its medicinal properties.
This mushroom is traditionally used in the treatment of
atherosclerosis, hepatitis, hyperlipidemia, dermatitis, and
cancer, and it has been shown to have immunomodulat-
ing and antimutagenic eﬀects both in vivo and in vitro.
Polysaccharides α-glycan and β-glycan are responsible for
the function of immunological and antitumoral stimulation
[15–17].
A. Blazeihas already been shown to be beneﬁcial in
insulin resistance related to type 2 diabetes, but no study has
shown the antioxidant potential of A. Blazei in vivo in DM
[17]. Thus, this study was designed to evaluate the oxidative
stress as well as the therapeutic eﬀect of A. Blazei in the pul-
monary tissue of animals with streptozotocin-induced DM.
2. Methods
2.1. Mushrooms. Air-dried mushrooms of the species Agari-
cus blazei Murill (C type) were a gift from Dr. Luiz Antˆ onio
Graciollo,DepartmentofEngeneering attheStateUniversity
of S˜ ao Paulo (UNESP), Brazil.
2.2. Preparation of A. blazei Aqueous Extract. Air-dried parts
(100g) were milled and the aqueous extracted was pre-
pared by infusion (1/10mushroom/solvent). The infusion
stood at room temperature for 30 minutes. After cooling
and ﬁltration, the extract was frozen and concentrated by
lyophilization for ﬁve days overnight, in order to obtain the
A. blazei aqueous extract.
2.3. Chemicals and Reagents. 2,2-Diphenil-1-picrylhidrazyl
(DPPH), hypoxanthine, xanthine oxidase, trolox, and sali-
cylic acid were purchased from Sigma (St. Louis, USA).
2.4. Phytochemical Screening. The phytochemical analysis
(ﬂavonoids, tannins, anthraquinones, alkaloids, saponins,
coumarins and cardiac glycosides) of A. blazei was carried
out according to the methods described by Harborne [18].
The thin layer chromatography analyses were performed
following systems and developers indicated by Wagner and
Bladt [19].
2.5. Hypoxanthine/Xanthine Oxidase Assay. The method
employed to assay the hydroxyl radical scavenging ability of
the extracts was based on the method of Owen et al. [20].
Brieﬂy, the extract was dissolved in the assay buﬀer (hypox-
anthine, Fe(III), EDTA and salicylic acid) at a concentration
of 2.0mg/mL and diluted appropriately (in triplicate) in
assay buﬀe rt oaﬁ n a lv o l u m eo f1 . 0 m Lg i v i n gar a n g eo f
0.1–2.0mg/mL. A 5μL aliquot of xanthine oxidase dissolved
in 3.2M (NH4)2SO4 was added to initiate the reaction.
The sample tubes were incubated for 3 hours at 37◦C,
at which time the reaction was complete. A 30μLa l i q u o t
of the reaction mixture was analyzed by HPLC using
chromatographic conditions as described by Owen et al. [21,
22]. Chromatographic analysis was done using a gradient
based on methanol/water/acetic acid with a μBondaPak C18
reverse phase column and detection at 325nm. The HPLC
equipment had a 2695 separation module and UV detector
2487. The hydroxylation of salicylic acid and hypoxanthine
were monitored at A = 325 and A = 278nm, respectively. The
amount of dihydroxyphenols (2,5-dihydroxibenzoic acid
and 2,3-dihydroxibenzoic acid) (2,5-DHBA and 2,3-DHBA)
produced by hydroxyl radical (OH•) attack on salicylic acid
was determined from standard curves prepared with the
respective pure dihydroxyphenols.
2.6. DPPH-Scavenging Assay. Scavenging of DPPH free
radical was measured using a modiﬁed method described
by Yamaguchi et al. [23] in which the diﬀerent methanolic
plant extracts were added to Tris–HCl (100mM) buﬀer,
pH 7.0, containing 250mM DPPH dissolved in methanol.
At least six diﬀerent dilutions of each extract were tested,
and allowed to stand 20 minutes in the dark, before
absorbance was measured at 517nm using a Shimadzu
spectrophotometer model UV-1602PC (Kyoto, Japan). The
experiment was conducted in triplicate. Antioxidant activity
(AOA) was expressed as IC50 (inhibitory concentration in
μg/mL of samples or positive controls necessary to reduce
the absorbance of DPPH by 50% compared to the negative
control). The lower the IC50, the higher is the AOA [23].
2.7. Animals and Experimental Protocol. The experimental
protocol used complied with the norms established by
the Ethical and Health Research Committee of the Group
of Research and Postgraduate Studies of the Hospital de
Cl´ ınicas of Porto Alegre as well as with the Principles for
Research Involving Animals (NAS). Only male Wistar rats
wereused,obtainedfromthebreedingcolonyoftheInstituto
de Ciˆ encias B´ asicas da Sa´ ude da Universidade Federal do Rio
Grande do Sul (UFRGS). The mean weight of animals at the
start of the study was 200–300grams. They were kept under
a 12:12 hours light/dark cycle (light from 7 a.m. to 7 p.m.)
in a temperature-controlled environment (22 ± 4◦C).
DM was induced by a single injection of streptozotocin
i.p. (STZ, Sigma Chemical Company, St. Louis,M O ,E U A )a t
ad oseo f70mg/Kgo fbod yw eight[24].STZwasdissolvedin
sodiumcitratebuﬀer(0.1M,pH4.5)andadministeredinthe
left abdominal region of the animal about 10 minutes after
dissolution in the buﬀer solution. The animals in the control
group received only NaCl 0.9% i.p. at the same volume of
the buﬀer used to dissolve STZ. The A. blazei extract was
diluted to the concentration of 0.1g/mL (10%) in a solution
of distilled water and left for 2 hours at room temperatureExperimental Diabetes Research 3
[25].Theadministrationroutewasgastricgavagewithaﬁnal
solution of 2mL and treatment was initiated from the 40th
day of diabetes induction. The animals were randomized
in the diﬀerent groups: control (CO), diabetic treated with
NaCl (DM), and diabetic treated with A. blazei (DM + A.
blazei). Blood samples were collected from the retro-orbital
plexus one day before induction, and 2 and 30 days after the
beginning of the experiment. At the end of the 60 days of
trialtheanimalswasinducetoeuthanasiabyexsanguination,
after anesthetized with xilasine and ketamine. Blood from
the retro-orbital plexus was sampled and the right lung was
dissected out and kept in 4% formaldehyde for histological
analysis. The left lung was removed and frozen at −80◦Cf o r
additional analyses.
2.8. Serum Analyses. The blood samples were placed into a
testing tube with heparin (Liquemine) to avoid coagulation.
The material was then centrifuged at 1.800 × gf o r1 5
minutes. The precipitate was discarded and the plasma
removed.
To determine glucose, cholesterol and triglycerides levels
we used the colorimetric enzymatic test (Kit Labtest, Bio
Diagn´ ostica) and absorbance was measured in spectropho-
tometer (CARY 3E-UV-Visible Spectrophotometer Varian).
Animals with a glucose concentration above 250mg/dL [26]
were considered as diabetic.
2.9. Biochemical Analyses of Oxidative Stress and Antioxidant
Assay. The lungs were homogenized with 9mL of phosphate
buﬀer(KCL140mM,phosphate20mM,pH7.4)pergramof
tissue. The protein concentration in these lung homogenates
was determined using a standard solution of bovine albumin
according to Lowry et al. [27].
Pulmonary lipoperoxidation was determined by the
method of thiobarbituric acid reactive substances (TBA-RS)
[28].
Superoxide dismutase (SOD) activity in the lung tissue
was determined using a technique based on the inhibition of
adrenochrome formation in epinephrine autoxidation [29].
Catalase (CAT) activity in the lung tissue was determined as
described elsewhere [30] and the determination of selenium-
dependent glutathione peroxidase in the lung tissue was
obtained through a technique consisting in the measure of
NADPH oxidation by glutathione reductase [31].
2.10. Histological Study. For the histological analysis the
samples were embedded in paraﬃn twice. Using a micro-
tome, the paraﬃn blocks were cut into 3-μms e r i a t e
sections. In the staining phase, the slides were immersed
in hematoxylin-eosin and picrosirius. In the dehydration
phase, the structures went through three containers with
absolute alcohol and two containers with xylol. Reading was
performed with light microscopy (Nikon Labophot) at 100×.
The analysis was performed by 2 pathologists who did not
know the study details.
2.11. Immunohistochemical Detection of iNOS. Immuno-
histochemical reactions were performed in the lung tis-
sue sections through the technique of streptavidin-biotin
peroxidase complex (StreptABC, DAKO). The slides were
previously coated by a silane solution (APTS, Sigma) diluted
in 4% acetone. 3-μm thick sections were obtained using
a mechanical microtome. The sections were then deparaf-
ﬁnized and successively immersed in xylol and ethanol
and submitted to antigenic recovery by irradiation heat
in pressure cooker (Eterna, Nigro) using citrate buﬀer
(10mM, pH 6.0) for 15 minutes. Peroxidase blocking was
performed using a hydrogen peroxide solution at 3%,
followed by incubation with primary antibody against NOS-
2 (iNOS, 1:40, Santa Cruz). The reactions were marked
with diaminobenzidine (DAB, Sigma) solution at 60mg%
and counterstained with Harris’s hematoxylin (Merck). For
each reaction a positive control was used to tissue that
was known to be positive for the tested antibody. Two
negative controls were also used, the ﬁrst one by absence
of the primary antibody and the second by removing the
secondary antibody during the reaction steps. The cases were
consideredasiNOS-positivewhenthebrowncolorationofat
least moderate intensity was visible in the cell cytoplasm and
in more than 10% of the cells.
2.12. Statistical Analysis. T h ed a t aa r ep r e s e n t e da sm e a n
± standard deviation (SD) and were analyzed through
statistical software SPSS 15.0. The variables were tested
for normality through the Kolmogorov-Smirnov test. One-
way analysis of variance (ANOVA) was used for intergroup
diﬀerences. Student Newman-Keuls post hoc test was used
for parametric variables and Kruskal-Wallis for the nonpara-
metric ones. The level of signiﬁcance used was P<. 05.
3. Results
3.1. Phytochemical Analyses. Phytochemical analyses of A.
blazeiindicatedthepresenceofsaponinsandalkaloids.Other
secondary metabolites such as anthraquinones, cardiac gly-
cosides, cumarins, ﬂavonoids, fenolic acids and tannins were
not detected.
3.2. Hypoxanthine/Xanthine Oxidase In Vitro Assay. The in
vitro antioxidant activity of the extract was determined
by monitoring the production of hydroxyl benzoic acids
(DHBA) as a product of the hydroxyl radical attack on
salicylic acid in the hipoxanthine-xanthine oxidase assay.
The reduction of total oxidation products as a function of
the concentration of A. blazei aqueous extract added to the
assay resulted in an in vitro antioxidant capacity in a dose-
dependent manner. The aqueous extract of A. blazei reduced
the formation of both DHBA species to 45.2 % in the highest
concentrationused(2mg/mL).TheIC50 valuewascalculated
and found to be 0.99mg/mL. A second type of mushroom
(Lentinula edodes) for which the authors did not ﬁnd the
presence of alkaloids was used as control sample (IC50 of
1.95mg/mL).Trolox (vitaminE)wasusedaspositive control
and displayed an IC50 of 0.34mg/mL (Figure 1).
3.3. DPPH-Scavenging Assay. The free radical scavenging
eﬀect of the both of A. blazei aqueous extract, L. edodoes
aqueous extract, as well as trolox, as positive control, was4 Experimental Diabetes Research
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Figure 1: Inhibition of the generation of reactive oxygen species
by aqueous extracts of aerial parts of Agaricus blazei (), Lentinula
edodes () and Trolox, used as positive control () using the
hypoxanthine/xanthine oxidase system. Data points are presented
as mean of ± SD, n = 3.
tested, using the DPPH free radical scavenging assay [23].
The IC50 values for A. blazei aqueous extract and for L.
edodes extract are shown in Table 1. The results of the free
radical scavenging eﬀect of trolox (IC50 = 0.02mg/mL), used
as positive control, was used to validate the assay. Although
thefreeradicalscavengingcapacitiesoftheextractswaslower
(higherconcentrationarenecessarytoreducetheabsorbance
of DPPH by 50%) than the eﬀect of trolox, the A. blazei
aqueous extract (with highest ﬂavanone content) presented
promising antioxidant activity with an IC50 of 1.77mg/mL.
L. edodes, on the other hand, had the lowest scavenging
activity (IC50 = 3.22mg/mL) which is in agreement with the
absence of alckloids in this species of mushroom.
3.4. Body Weight and Serum Analyses. The body weight of
diabetic animals was signiﬁcantly reduced, and A. Blazei-
t r e a t e da n i m a l sl o s tw e i g h ts t i l lm o r e( Table 2). The A. Blazei
extract apparently reduced glycemia in the diabetic rats (P<
.01) but the glycemic curve was similar across diabetic and
treated animals. However, A. Blazei signiﬁcantly reduced the
total cholesterol and triglycerides levels (P<. 01). The DM
a n dD M+A. Blazei groups had diﬀerent sample sizes due
the higher mortality of the animals of DM group during the
experiment.
3.5. Biochemical Analysis and Oxidative Stress. A. Blazei
signiﬁcantly reduced (P<. 05) the lipoperoxidation levels
as determined by TBA-RS (Table 3). However, activity of
antioxidant enzymes SOD and CAT did not show any
diﬀerences between the groups. Enzyme GPx activity was
signiﬁcantly increased in the diabetic group and reduced in
the A. Blazei-treated group (P<. 05).
3.6. Histological Analysis. STZ-induced Diabetes Mellitus
caused serious vascular injury to the pulmonary tissue
(Figure 2(c)), where alveolar changes such as septa rupture
were also evidenced. Picrosirius staining revealed an expan-
sion of the conjunctive tissue in the alveolocapillary space of
the diabetic group (Figure 2(d)) and an apparent reversion
of this pattern in the Ab-treated group (Figure 2(f)).
3.7. Immunohistochemical Analysis of iNOS. Figure 3 shows
iNOS distribution in the lung tissue as detected through
immunohistochemistry. The positive stain in brown seen in
the pulmonary bronchial epithelium and capillary endothe-
lium in the DM group indicated iNOS positivity. iNOS
staining was less apparent in the A. Blazei group and absent
in the CO group.
4. Discussion
Results of the free radical scavenging eﬀect of the A. blazei
aqueous extract in the hipoxantine/xanthine oxidase in
vitro assay, and in the DPPH free radical scavenging assay,
showed a signiﬁcant in vitro antioxidant activity. In both
assays the extract expressed a higher antioxidant activity, in
comparison with the aqueous extract of L. edodes,w h i c h
is another species of mushroom and which presents only
saponins, but not alkaloids, or ﬂavonoids or tannins. It
has been suggested by Ribeiro et al. that the antioxidant
activity might be related to the presence of alkaloids in the
mushroom. In other words, higher alkaloid concentrations
generate better antioxidant activity [32].
The main ﬁnding of this study was the reduction of
pulmonary lipoperoxidation in rats with streptozotocin-
induced diabetes after treatment with Agaricus blazei.P r e -
vious studies have shown a glycemia-reducing eﬀect, which
decreases insulin resistance and enhances the release of it by
β-pancreatic cells[17, 33]. However, A. Blazei treatmenthere
showed a beneﬁcial eﬀect regarding the variables related to
the oxidative stress, despite not reducing hyperglycemia.
Kim et al. described antidiabetogenic eﬀects of β-
glucanes extracted from A. Blazei and its enzymatically
hydrolyzed oligosacharides, evaluating the in vitro and in
vivo eﬀects in culture of β-pancreatic cells and in animals
with streptozotocin-induced diabetes. After treatment with
β-glucanes and oligosacharide the animals presented reduc-
tions in glycemia, triglycerides, and cholesterol levels and in
atherosclerotic activity [34]. In our study, the treatment was
performedusingagrossextractofA.Blazei,withoutisolating
any of its compounds, and this is probably the explanation
for the lack of antiglycemic action.
The extract of A. Blazei demonstrated in vitro and in
vivo antioxidant activity, however the treatment signiﬁcantly
reduced the weight of the animals. This fact could be
explained due to high doses of A. blazei extract used in this
experiment,diﬀerentlyofdosesusedinothersstudiesthatdo
not demonstrate weight reduction [34]. However, in a study
to evaluate 90-day subchronic toxicity of an aqueous extract
in rats, there were no consistent treatment-related changes in
clinical signs, body weight and food consumption at the dose
of 2654mgkg−1 for male rat, a higher dose than used in our
study [15]. More studies were necessary to evaluate the toxic
eﬀect of A. Blazei in these doses, with the analysis of speciﬁc
variables.
GPx was signiﬁcantly increased in the diabetic group
and was signiﬁcantly reduced after A. Blazei treatment. ThisExperimental Diabetes Research 5
Table 1: Inhibition of DPPH∗,I C 50 values for the DPPH assay of aqueous extracts of Agaricus blazei and Lentinula edodes mushrooms, and
trolox.
Sample Inhibition of DPPH (%)
Concentration 0.1μg/mL 0.25mg/mL 0.5mg/mL 1mg/mL 2mg/mL IC50 (mg/mL)
Trolox 91.27 93.53 96.71 99.03 99.89 0.02 ± 0.00
Agaricus blazei 7.28 10.77 17.09 46.32 48.81 1.77 ± 0.08
Lentinula edodes 2.19 4.68 8.33 18.56 30.63 3.22 ± 0.12
Mean ± standard deviation of three individual determinations. Results were based on the values measured at 20 minutes. Trolox was used as positive control.
∗DPPH: 2,2-diphenyl-1-picrylhydrazyl.
Table 2: Changes in body weight and glucose, cholesterol and triglycerides plasma levels.
N Weight (g) Glucose (mg/dL) Total Cholesterol (mg/dL) Triglycerides (mg/dL)
CO 5 442.00 ± 10.95 244.17 ± 68.01 28.35 ± 4.62 61.33 ± 33.43
DM 8 306.22 ± 32.11† 482.37 ± 36.81∗ 42.88 ± 6.44∗ 161.00 ± 76.80##
DM + A. Blazei 12 282.00 ± 44.11# 468.19 ± 62.46# 33.99 ± 5.23∗∗ 45.87 ± 10.61∗∗
Data appear as mean ± SD. CO: Control, DM: Diabetes Mellitus and DM + A. Blazei:D i a b e t e sM e l l i t u s +Agaricus blazei.
†P <. 001 CO versus DM.
#P <. 05 DM versus DM + A. Blazei.
∗P <. 01 CO versus DM.
∗∗P <. 01, DM versus DM + A. Blazei.
##P <. 05 CO versus DM.
Table 3: Biochemical analyses of oxidative stress in lung tissue.
TBARS (nmoles/mg of protein) SOD (U/mg de prote´ ın) CAT (pmoles/mg de protein) GPx (nmoles/mg de protein)
CO 0.18 ± 0.02 76.33 ± 3.39 0.10 ± 0.04 0.41 ± 0.07
DM 0.43 ± 0.09∗ 69.32 ± 11.73 0.18 ± 0.07 1.10 ± 0.53∗
DM + A. Blazei 0.33 ± 0.04∗∗ 74.84 ± 8.75 0.15 ± 0.03 0.45 ± 0.09∗∗
Data appear as mean ± SD. CO: Control, DM: Diabetes Mellitus and DM + A. Blazei:D i a b e t e sM e l l i t u s +Agaricus blazei.
∗P <. 01 CO versus DM.
∗∗P <. 05 DM versus DM + A. Blazei.
(a) (b) (c)
(d) (e) (f)
Figure 2: Histology of lung tissue stained by HE (a, c and e) and picrosirius (b, d and f). Magniﬁcation 100×: (a) and (b): Control, (c) and
(d): Diabetes Mellitus, (e) and (f): Diabetes Mellitus treated with Agaricus blazei.6 Experimental Diabetes Research
(a)
(b)
(c)
Figure 3: iNOS immunohistochemistry in lung tissue. Magniﬁca-
tion400×:Therewasnostaininginthecontrolgroup(a);reduction
in the treated group (b) versus DM (c).
increase in GPx can account for the diminished levels of
reduced glutathione, as it is the main substrate regulating its
activity. Gumieniczek et al. demonstrated that in experimen-
tal DM the pulmonary oxidative stress is present because of
the reduction of antioxidant enzyme activity and increased
lipoperoxidation. Such changes are more signiﬁcant after
weeks following induction. During DM there is a decrease of
Cu,Zn-SOD activity and an increase of catalase activity [35].
In our study, neither SOD nor catalase activity were changed
in none of the diﬀerent groups. A possible explanation for
our ﬁndings diﬀering from those of Gumieniczek is that in
ourstudytheanalysisofantioxidantenzymeswasperformed
earlier.
In our experimental model numerous histological alter-
ations were observed in the pulmonary system. These
alterations are in agreement with those reported in the
literature [7, 36, 37], especially as regards the increase in
the conjunctive tissue and thickening of the basal lamina
observed through the technique of picrosirius staining.
After treatment with A. Blazei such alterations became less
evident. The formation of intra-and intermolecular binding
with collagen, resulting from the process of glycosilation,
leads to structural alterations in tissue proteins such as
increaseinrigidity,resistancetoproteolyticdigestionandthe
extracellular matrix (including ﬁbronectin, procollagen α2,
type III, IV and VI collagen, and laminina) [38, 39]. In our
study, the main factor for the reversion of this process after
treatmentwithA. Blazei can be explained by the reduction of
damage resulting from the oxidative stress demonstrated by
the reduction of pulmonary lipoperoxidation.
A long term hyperglycemic state is related to alterations
in iNOS expression in several tissues [10]. In the immuno-
histochemical analysis of our study iNOS was signiﬁcantly
increased in the pulmonary tissue of the diabetic rats and
signiﬁcantlydecreasedwhentheanimalsweretreatedwithA.
Blazei. Studies have demonstrated that mRNA expression of
endothelial nitric oxide synthase (eNOS) is reduced, whereas
iNOS may be increased together with the generation of cyclic
guanosine monophosphate (c-GMP) [14].
In a recently published study, lipoperoxidation, super-
oxide dismutase activity, and the distribution of iNOS and
eNOS isoforms were evaluated in the lung tissue of diabetic
rats. An increase in the oxidative stress concomitant with
the increased iNOS in the lung tissue of diabetic rats
was observed, which was reversed in the group treated
with antioxidant α-lipoic acid [40]. These ﬁndings are in
agreement with those reported in the present work, such
as the observed increased oxidative stress, the histological
pulmonary alterations, and the eﬀect of an antioxidant
therapy in this DM model.
The present study demonstrates the beneﬁcial eﬀect of
A. Blazei aqueous extract regarding oxidative stress vari-
ables and pulmonary morphopathology in streptozotocin-
induceddiabetes.Theseﬁndingsmaycontributesigniﬁcantly
to a better understanding of the pulmonary physiopathology
in DM. Our study is also relevant and with regard to the
therapeutic potential of A. Blazei.
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